ClinicalTrials.gg
Not yet recruitingNCT07391826Updated Feb 6, 2026

Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX

A Phase 2 interventional study of megestrol acetate oral suspension + serplulimab + SOX and serplulimab + SOX in Stage III Gastric Cancer, sponsored by The First Affiliated Hospital with Nanjing Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing serplulimab in Stomach Neoplasms — 8 open to participants now, 11 under way, none of them phase 3. serplulimab · Stomach Neoplasms.

Planned enrollment
8th of 14
48 · median 59
Started
2026
with 3 others
Phase 2
13 of 14
8 open now
Primary completion
2026-12
later than 3 of 10 live
Registered
11th of 14
by date
Lead sponsor
1 of 14
The First Affiliated Hospital with Nanjing Medical University

Among the 14 studies testing serplulimab in Stomach Neoplasms, this one is the 8th largest by planned enrollment, is one of 4 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 3 of the 10 other live ones, and was the 11th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 14 studies testing serplulimab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About serplulimab

serplulimab: first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing serplulimab in Stomach Neoplasms, or all of them as a file.
02

Study summary

This study is an open-label, prospective, randomized controlled phase II clinical study. The purpose is to evaluate the efficacy and safety of megestrol acetate oral suspension for patients with cachexia and cStage III gastric/gastroesophageal junction adenocarcinoma who receive neoadjuvant therapy with serplulimab combined with SOX. This study intends to include 48 patients with locally advanced gastric adenocarcinoma who have not received any treatment, meet the diagnosis of cachexia, and are operable as research subjects. It is expected that 32 patients will be included in the experimental group and 16 patients will be included in the control group, with an inter-group ratio of approximately 2:1. After signing the informed consent, the patients will be screened and meet the inclusion and exclusion criteria. The groups will be assigned according to the random results. The patients will receive or not receive megestrol acetate oral suspension during the 3 cycles of serplulimab SOX regimen before surgery. After the second and third cycles of medication, the efficacy of neoadjuvant therapy and the possibility of radical gastric cancer D2 resection will be evaluated by imaging examinations, and radical gastric cancer surgery will be performed within 2-6 weeks after the third dose is completed. The treatment of postoperative patients will be decided by clinicians and patients based on actual clinical diagnosis and treatment.

Patients must be given study drug treatment within 7 days after randomization. The dosing window for each cycle after the first dose is ±7 days. Before each dose, patients must complete the corresponding examinations specified in the protocol to assess the safety and tolerability of the treatment.

Dosage regimen:

  • Treatment group: megestrol acetate oral suspension + serplulimab + SOX
  • Control group: serplulimab + SOX
03

Conditions studied

  • Stage III Gastric Cancer

Browse trials for

Keywords

  • gastric/gastroesophageal junction adenocarcinoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary signing of written ;
  2. Age at enrollment ≥ 18 years and ≤ 80 years;
  3. (ECOG, see Appendix 4) physical status score of 0-2;
  4. Expected survival ≥ 6 months;
  5. According to the 8th edition of AJCC gastric cancer staging, patients with cStage III (cT3-4aN1-3M0) assessed by abdominal CT and diagnosed with G/GEJ adenocarcinoma by gastroscopy and pathology, and only Siewert III type and Siewert II type subjects who do not require combined thoracotomy are allowed to be enrolled in gastroesophageal junction (GEJ) cancer;
  6. Meet the diagnostic criteria for cachexia (based on Fearon diagnostic criteria).

    Diagnostic criteria for cachexia: any of the following combined with anorexia or systemic inflammatory response: (1) involuntary weight loss of >5% in 6 months; (2) \<18.5 kg/m2, and involuntary weight loss of >2% in 6 months; (3) limb skeletal muscle index meets the diagnostic criteria for sarcopenia (male \<7.26 kg/m²; female \<5.45 kg/m²), and involuntary weight loss of >2% in 6 months.

  7. Before enrollment, a gastrointestinal surgeon and an imaging physician jointly evaluated and determined that the tumor was cStage III and eligible for R0 resection with the purpose of cure. The patient agreed to undergo radical surgery and was judged by the surgeon to have no to surgery;
  8. No previous systemic treatment for the current disease, including surgical treatment, anti-tumor chemoradiotherapy/immunotherapy, etc.;
  9. Good cardiac function, and resection with the purpose of cure can be performed. If clinically indicated, patients with underlying ischemic, valvular heart disease or other severe heart disease should be evaluated by a cardiologist before surgery;
  10. Normal function of major organs
  11. Female patients must meet the following requirements:

    • Menopausal (defined as no menstruation for at least 1 year, and no other confirmed cause other than menopause), or surgical sterilization (ovarian and/or uterine removal), or patients of must meet the following requirements at the same time:
    • A negative pregnancy test within 7 days before the first medication;
    • Agree to use measures with an annual failure rate of \< 1% or maintain abstinence (avoid heterosexual intercourse) (from signing the informed consent form to at least 120 days after the last dose of the trial drug, and at least 9 months after surgery (contraceptive methods with an annual failure rate of \< 1% include bilateral tubal ligation, male sterilization, correct use of hormonal contraceptives that can inhibit ovulation, hormone-releasing intrauterine devices, and copper-containing intrauterine devices.);
    • No breastfeeding.
  12. Male patients must meet the following requirements: agree to abstinence (avoid heterosexual intercourse) or take contraceptive measures. The contraceptive measures are as follows: When the partner is a woman of childbearing age or the partner is pregnant, the male patient must abstain from sex or use condoms correctly for contraception for at least 120 days after the last dose of the trial drug and at least 9 months after surgery. The reliability of sexual abstinence should be evaluated with reference to the duration of the clinical study, patient preferences, and daily lifestyle. Regular abstinence (e.g., calendar day, ovulation period, basal body temperature, or post-ovulation contraceptive methods) and ejaculation outside the body are unqualified contraceptive methods;
  13. The subject read and fully understood the patient instructions and signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. The patient has had other malignant tumors in the past (within 5 years) or concurrently. Patients with cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, stage I lung cancer, stage I colorectal cancer, etc. can be included in the group;
  2. Patients who are preparing for or have received organ or bone marrow transplantation in the past;
  3. Patients who have received blood transfusion within 2 weeks before the first medication, or have a history of bleeding, and have any severe bleeding events of grade 3 or above in CTCAE5.0 within 4 weeks before screening;
  4. Patients with abnormal coagulation function and bleeding tendency ( is in the normal value > 1.5 without the use of anticoagulants); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogs; On the premise that the international normalized ratio (INR) of prothrombin time is ≤1.5, low-dose warfarin (1 mg orally, once a day) or low-dose aspirin (daily dose not exceeding 100 mg) is allowed for preventive purposes;
  5. Arterial/venous thrombotic events within 6 months before screening, such as cerebrovascular accident (including ), deep vein thrombosis (except for venous thrombosis caused by intravenous catheterization during previous chemotherapy, which is judged by the researcher to have been cured) and pulmonary embolism;
  6. Myocardial infarction and poorly controlled arrhythmia (including ≥450 ms for men and ≥470 ms for women) within 6 months before the first medication (QTc interval is calculated by Fridericia formula);
  7. standard III-IV heart failure or cardiac ultrasound examination: (left ventricular ejection fraction) \<50%;
  8. Urinalysis indicates urine protein ≥++ and confirms that the 24-hour urine protein quantification is >1.0 g;
  9. Pleural effusion or peritoneal effusion with clinical symptoms that require clinical intervention;
  10. (HIV) infection;
  11. Active pulmonary tuberculosis;
  12. Long-term unhealed wounds or incompletely healed fractures;
  13. Patients with past or current interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe lung function impairment, etc., which may interfere with the detection and treatment of suspected drug-related pulmonary toxicity;
  14. Patients with known active or suspected diseases, except those who are in a stable state of the disease at the time of enrollment (systemic therapy is not required);
  15. Patients with a history of severe chronic autoimmune diseases, such as systemic lupus erythematosus, etc.; patients with a history of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, and a history of chronic diarrheal diseases such as irritable bowel syndrome; patients with a history of sarcoidosis or tuberculosis; patients with a history of active , , and HIV infection; patients with well-controlled non-severe immune diseases, such as dermatitis, arthritis, psoriasis, etc. can be enrolled. Patients with hepatitis B virus titer \< 500 copies/ml can be enrolled;
  16. Patients who need to receive systemic (> 10 mg/day prednisone effective dose) or other immunosuppressive drugs within 14 days before the first medication or during the study. However, the following conditions are allowed to be enrolled: In the absence of active autoimmune diseases, patients are allowed to use topical or inhaled steroids, or adrenal hormone replacement therapy with a dose of ≤ 10mg/day prednisone effective dose;
  17. Any active infection requiring systemic anti-infective treatment within 14 days before the first medication, except for prophylactic antibiotic treatment (such as prevention of urinary tract infection or );
  18. treatment within 28 days before the first medication, except for inactivated viral vaccine for seasonal influenza;
  19. Previously received antibody/drug treatment for immune checkpoints, such as , PD-L1, CTLA-4 inhibitors, etc.;
  20. Receiving other drug-related clinical research treatment; patients who are undergoing other testing or surgical clinical research can be enrolled;
  21. Known history of allergy or intolerance to any study drug or its components;
  22. Patients have a history of alcoholism, drug abuse and drug abuse. Patients who have stopped drinking can be included in the group;
  23. Patients who do not follow the doctor's advice, do not use the medicine according to the regulations, or have incomplete information, which may affect the judgment of efficacy or safety;
  24. Pregnant or lactating female patients;
  25. Any condition that affects gastrointestinal absorption, such as dysphagia, a history of gastrectomy or uncontrollable vomiting; tube feeding or parenteral nutrition; anorexia nervosa, anorexia caused by mental illness or pain that makes it difficult to eat.
  26. Taking or planning to take other appetite or weight-increasing drugs, such as: adrenal corticosteroids (except for short-term use of dexamethasone during chemotherapy), androgens, progesterone drugs, thalidomide, olanzapine and anamorelin or other appetite stimulants.
  27. Patients with Cushing's syndrome, adrenal or pituitary insufficiency; patients with uncontrolled diabetes.
  28. women with a history of abnormal vaginal bleeding within one year; premenopausal women with a history of endometrial thickening (>15mm) within one year.
  29. Any arterial thromboembolic event within 6 months before the first dose, venous thromboembolic event of 5.0 grade 3 or above (requiring urgent medical intervention, such as pulmonary embolism or intracardiac embolism), transient ischemic attack, cerebrovascular accident, hypertensive crisis or hypertensive encephalopathy; acute exacerbation of chronic obstructive pulmonary disease within 1 month before the first dose; current hypertension and systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg after oral antihypertensive drug treatment.
  30. History of severe bleeding tendency or coagulation disorder; bleeding symptoms within 1 month before the first dose, including but not limited to gastrointestinal bleeding, hemoptysis (defined as coughing up or coughing up ≥1 teaspoon of fresh blood or small blood clots or only coughing up blood without sputum, blood in sputum is allowed), nasal bleeding (excluding epistaxis and retractile blood in nose).
  31. Patients with other severe, acute and chronic diseases that may increase the risk of participating in the study and taking the study drugs, and who are judged by the researchers to be unsuitable for participating in the clinical study.
  32. Other conditions that the researchers judge to be unsuitable for this clinical trial.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Treatment group

    megestrol acetate oral suspension + serplulimab + SOX

    Drug: megestrol acetate oral suspension + serplulimab + SOX

  • Experimental
    control group

    serplulimab + SOX

    Drug: serplulimab + SOX

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of patients whose weight did not decrease

    The proportion of subjects with a weight loss of no more than 2 kg from the initiation of neoadjuvant therapy to the time immediately preceding radical surgery.

    Time frame: From the date of the first neoadjuvant therapy until the date of radical surgery,assessed up to 6 months

Secondary outcomes

  1. appetite improve

    The proportion of subjects whose appetite improved based on the anorexia/cachexia subscale-12,A/CS-12 scale during neoadjuvant treatment, The total score ranges from 0 to 48, with lower scores indicating poorer appetite status in patients.

    Time frame: From the date of the first neoadjuvant therapy until the date of radical surgery,assessed up to 6 months

  2. Quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire(EORTC QLQ-C30)

    The total score of this scale ranges from 0 to 100. The higher the score of the functional scale or the overall quality of life, the better the function or overall quality of life.

    Time frame: From the date of the first neoadjuvant therapy until the date of radical surgery,assessed up to 6 months

  3. CRP indicators

    The level of change in CRP during neoadjuvant treatment.

    Time frame: From the date of the first neoadjuvant therapy until the date of radical surgery,assessed up to 6 months

  4. IL-6 indicators

    The level of change in IL-6 during neoadjuvant treatment.

    Time frame: From the date of the first neoadjuvant therapy until the date of radical surgery,assessed up to 6 months

  5. TNF-α indicators

    The level of change in TNF-α during neoadjuvant treatment.

    Time frame: From the date of the first neoadjuvant therapy until the date of radical surgery,assessed up to 6 months

  6. serum nutritional indicators (albumin, hemoglobin)

    The level of change in nutritional indicators (albumin, hemoglobin) during neoadjuvant treatment.

    Time frame: From the date of the first neoadjuvant therapy until the date of radical surgery,assessed up to 6 months

  7. The level of change in L3 skeletal muscle index (L3 SMI)

    The level of change in L3 skeletal muscle index (L3 SMI) during neoadjuvant treatment.

    Time frame: From the date of the first neoadjuvant therapy until the date of radical surgery,assessed up to 6 months

  8. The number of completed neoadjuvant treatment cycles

    Three cycles of neoadjuvant therapy are planned, with assessment of whether the number of cycles is reduced due to reasons such as subject intolerance.

    Time frame: From the date of the first neoadjuvant therapy until the date of radical surgery,assessed up to 6 months

  9. The number of the occurrence of drug dose reduction

    A drug dosage reduction of more than 15% is defined as a dosage reduction.

    Time frame: From the date of the first neoadjuvant therapy until the date of radical surgery,assessed up to 6 months

  10. pathological response

    Pathological complete remission (pCR) rate:It is defined as the absence of grossly visible tumor residue in gastric cancer resection specimens following neoadjuvant therapy, with no tumor cells identified microscopically after extensive sampling of the primary tumor site.

    Time frame: Assessment shall be completed within one week following radical surgery.

Other outcomes

  1. Immune microenvironment alterations during treatment

    Assessment of the immune microenvironment is performed based on the proportions of T cell subsets.

    Time frame: From the date of the first neoadjuvant therapy until the date of radical surgery,assessed up to 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2026, 10 months later.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 10 months is below that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Feb 6, 2026
StartEst.
Feb 15, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07391826
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Feb 15, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Megestrol Acetate · Serplulimab

Start the discussion